Shoshana B Ginsburg1, Pekka Taimen2, Harri Merisaari3,4,5, Paula Vainio2, Peter J Boström6, Hannu J Aronen3,7, Ivan Jambor3,4,7, Anant Madabhushi1. 1. Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA. 2. Department of Pathology, University of Turku and Turku University Hospital, Turku, Finland. 3. Department of Diagnostic Radiology, University of Turku, Turku, Finland. 4. Turku PET Centre, University of Turku, Turku, Finland. 5. Department of Information Technology, University of Turku, Turku, Finland. 6. Department of Urology, Turku University Hospital, Turku, Finland. 7. Medical Imaging Centre of Southwest Finland, Turku University Hospital, Turku, Finland.
Abstract
PURPOSE: To develop and evaluate a prostate-based method (PBM) for estimating pharmacokinetic parameters on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) by leveraging inherent differences in pharmacokinetic characteristics between the peripheral zone (PZ) and transition zone (TZ). MATERIALS AND METHODS: This retrospective study, approved by the Institutional Review Board, included 40 patients who underwent a multiparametric 3T MRI examination and subsequent radical prostatectomy. A two-step PBM for estimating pharmacokinetic parameters exploited the inherent differences in pharmacokinetic characteristics associated with the TZ and PZ. First, the reference region model was implemented to estimate ratios of Ktrans between normal TZ and PZ. Subsequently, the reference region model was leveraged again to estimate values for Ktrans and ve for every prostate voxel. The parameters of PBM were compared with those estimated using an arterial input function (AIF) derived from the femoral arteries. The ability of the parameters to differentiate prostate cancer (PCa) from benign tissue was evaluated on a voxel and lesion level. Additionally, the effect of temporal downsampling of the DCE MRI data was assessed. RESULTS: Significant differences (P < 0.05) in PBM Ktrans between PCa lesions and benign tissue were found in 26/27 patients with TZ lesions and in 33/38 patients with PZ lesions; significant differences in AIF-based Ktrans occurred in 26/27 and 30/38 patients, respectively. The 75th and 100th percentiles of Ktrans and ve estimated using PBM positively correlated with lesion size (P < 0.05). CONCLUSION: Pharmacokinetic parameters estimated via PBM outperformed AIF-based parameters in PCa detection. J. Magn. Reson. Imaging 2016;44:1405-1414.
PURPOSE: To develop and evaluate a prostate-based method (PBM) for estimating pharmacokinetic parameters on dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) by leveraging inherent differences in pharmacokinetic characteristics between the peripheral zone (PZ) and transition zone (TZ). MATERIALS AND METHODS: This retrospective study, approved by the Institutional Review Board, included 40 patients who underwent a multiparametric 3T MRI examination and subsequent radical prostatectomy. A two-step PBM for estimating pharmacokinetic parameters exploited the inherent differences in pharmacokinetic characteristics associated with the TZ and PZ. First, the reference region model was implemented to estimate ratios of Ktrans between normal TZ and PZ. Subsequently, the reference region model was leveraged again to estimate values for Ktrans and ve for every prostate voxel. The parameters of PBM were compared with those estimated using an arterial input function (AIF) derived from the femoral arteries. The ability of the parameters to differentiate prostate cancer (PCa) from benign tissue was evaluated on a voxel and lesion level. Additionally, the effect of temporal downsampling of the DCE MRI data was assessed. RESULTS: Significant differences (P < 0.05) in PBM Ktrans between PCa lesions and benign tissue were found in 26/27 patients with TZ lesions and in 33/38 patients with PZ lesions; significant differences in AIF-based Ktrans occurred in 26/27 and 30/38 patients, respectively. The 75th and 100th percentiles of Ktrans and ve estimated using PBM positively correlated with lesion size (P < 0.05). CONCLUSION: Pharmacokinetic parameters estimated via PBM outperformed AIF-based parameters in PCa detection. J. Magn. Reson. Imaging 2016;44:1405-1414.
Authors: Thomas E Yankeelov; Jeffrey J Luci; Martin Lepage; Rui Li; Laura Debusk; P Charles Lin; Ronald R Price; John C Gore Journal: Magn Reson Imaging Date: 2005-05 Impact factor: 2.546
Authors: Martin Lowry; Bashar Zelhof; Gary P Liney; Peter Gibbs; Martin D Pickles; Lindsay W Turnbull Journal: Invest Radiol Date: 2009-09 Impact factor: 6.016
Authors: G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz Journal: Radiology Date: 1997-06 Impact factor: 11.105
Authors: Barış Türkbey; Marcelino Bernardo; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: Diagn Interv Radiol Date: 2011-09-16 Impact factor: 2.630
Authors: Julio Cárdenas-Rodríguez; Christine M Howison; Terry O Matsunaga; Mark D Pagel Journal: Magn Reson Imaging Date: 2013-04-11 Impact factor: 2.546
Authors: Milica Medved; Greg Karczmar; Cheng Yang; James Dignam; Thomas F Gajewski; Hedy Kindler; Everett Vokes; Peter MacEneany; Myrosia T Mitchell; Walter M Stadler Journal: J Magn Reson Imaging Date: 2004-07 Impact factor: 4.813
Authors: Silvin Paul Knight; Jacinta Elizabeth Browne; James Frances Mary Meaney; Andrew John Fagan Journal: MAGMA Date: 2017-04-10 Impact factor: 2.310